OXO Chemie (Thailand)

OXO Chemie (Thailand) is a pharmaceutical company based in Bangkok, specializing in the development and commercialization of chlorite-based therapeutic agents. The company's core technology revolves around WF10 (Tetrachlorodecaoxide), a stabilized chlorite solution marketed under the brand names Immunokine and Oxovasin. WF10 acts as an immune modulator and redox-active agent that targets dysfunctional red blood cells to treat inflammatory conditions and diabetic complications. The drug is currently approved in Thailand for the treatment of diabetic foot ulcers and hemorrhagic radiation cystitis. OXO Chemie (Thailand) works in close partnership with OXO Translational Science GmbH in Germany to advance its clinical pipeline, which includes programs for diabetic vascular complications and diabetic kidney disease. The company is led by its founder, Dr. Friedrich-Wilhelm Kuehne, who pioneered the development of TCDO technology. Its research focuses on the redox-active clearance of highly glycated red blood cells to restore endothelial integrity and improve microcirculation.